Core Viewpoint - The announcement by former President Trump regarding the potential price reduction of the weight loss drug Ozempic has led to significant declines in the stock prices of Eli Lilly and Novo Nordisk, with both companies experiencing drops of over 4% in early trading [1] Company Summary - Eli Lilly's stock price fell to $783.84, while Novo Nordisk's stock price dropped to $53.66 following Trump's comments [1] - Trump's statement indicated that the price of Ozempic, currently priced at approximately $1,000 per month in the U.S., could be reduced to as low as $150 per month [1] - Eli Lilly's similar drugs include Wegovy and Zepbound, which may also be affected by the pricing discussions [1] Industry Summary - The potential price reduction for Ozempic could significantly impact the pharmaceutical industry, particularly in the weight loss drug segment [1] - The Centers for Medicare & Medicaid Services, represented by Mehmet Oz, clarified that negotiations regarding the drug prices are still ongoing, indicating that the situation remains fluid [1]